Compare General Mills, Inc. (GIS) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Illumina, Inc. — how do they compare? General Mills, Inc. trades at $32.29 (market cap $17.43B), while Illumina, Inc. trades at $278.17 (market cap $39.95B). The key difference: Illumina, Inc. is far larger — about 2.3× General Mills, Inc.'s market cap, and General Mills, Inc. pays a 7.49% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Mills, Inc. for 106 Days and Illumina, Inc. for 83 Days on average.
| GIS | ILMN | |
|---|---|---|
Market Cap | $17.43B | $39.95B |
Volume | 16,554,362 | 3,169,503 |
Sector | Consumer Staples | Health |
52-Week High | $49.36 | $293.69 |
52-Week Low | $31.67 | $91.00 |
Typical Hold Time | 106 Days | 83 Days |
Enterprise Value | $30.61B | $41.31B |
Dividend Yield | 7.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $32.59, up 2.58% today, amid a bearish technical outlook. The stock shows mixed fundamentals with a low P/E of 9.23 and a dividend yield supported by a $0.61 quarterly payout, but profitability metrics like a negative net income margin and ROE highlight challenges. Recent Q1 2027 earnings beat expectations, yet revenue trends are declining, and a CEO transition adds uncertainty. Analyst consensus is cautious with a $36.00 price target and a majority hold rating.
The outlook remains guarded due to margin pressures and competitive headwinds, though the dividend offers income appeal. Risks include potential earnings volatility and high debt levels. Upside depends on successful execution of cost-saving initiatives and volume recovery, but near-term performance may be constrained by macroeconomic factors.
ILMN trades at $264.40, down 1.25% on the day, but remains near its recent 52-week high of $278.99 (Defense World, 2026-10-01). The stock has surged 94.9% year-to-date (Zacks Investment Research, 2026-09-24), supported by strong earnings beats in recent quarters and a bullish technical trend. Fundamentals show a significant turnaround, with 2025 net income reaching $850 million after prior losses, though valuation ratios like a P/E of 49.36 are elevated. The pending inclusion in the S&P 500 (PRNewsWire, 2026-09-04) adds a positive catalyst.
The outlook is positive, driven by sequencing growth, AI integration in genomics, and improved profitability. However, risks include high valuation sensitivity, cost volatility, and competitive pressures in the life sciences sector. Analyst consensus is bullish with a 54% buy rating, but the average price target of $241 suggests limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
